Trial reportEuropean heart journal2002
Short-term effects of atorvastatin on C-reactive protein.
Trial report in European heart journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00795912 (A Study Of The Usage Of Statins In A Community Heart Failure Population), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Lipid-lowering efficacy of atorvastatin.The Cochrane database of systematic reviews · 2015 · on this mapPooled it
- Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study.Frontiers in public health · 2022Trial
- Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial).Journal of cardiovascular electrophysiology · 2011Trial
- Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie · 2005Trial
- Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.JCI insight · 2019Article
- Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion.Heart and vessels · 2015Observational
- Article
- Role of C-reactive protein when prescribing a statin.Current atherosclerosis reports · 2012Review
- Statins as first-line therapy for acute coronary syndrome?Experimental and clinical cardiology · 2012Article
- Association of statin prescription with small abdominal aortic aneurysm progression.American heart journal · 2010Article
- High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion.Internal and emergency medicine · 2009Article
- Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease.Psychopharmacology · 2009Article
- Statins and biomarkers of inflammation.Current atherosclerosis reports · 2007Review
- Review
- Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?Experimental and clinical cardiology · 2005Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. METHODS AND
resultsOne hundred and fifty-five randomly selected patients from the SWiss Intervention Trial for lowering CHolesterol (SWITCH) were assessed for high sensitivity CRP, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides at baseline, and after 1 and 3 months of treatment with atorvastatin at various doses to reach pre-defined lipid target values. The median decrease of cholesterol was 28% after 1 month and 35% after 3 months. LDL-cholesterol was decreased by 37% and 45%, HDL-cholesterol was increased by 7% and 8%, respectively. Patients with a low CRP baseline concentration (lowest quartile <1.34 mg. l(-1)) displayed no significant change, whereas patients in the other quartiles showed a significant decrease, of 22% to 40% (P -value <0.05 to <0.001) at 1 month and of 32% to 36% after 3 months compared to baseline. The decrease in CRP lowering was thus fully established by 1 month and this response was independent of lipid and lipoprotein changes as well as atorvastatin doses.
conclusionAtorvastatin significantly decreases CRP concentrations after 4 weeks of therapy. These results may be important with respect to the early benefit of statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.